Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Corrigendum to "The Biological Foundation of the Genetic Association of TOMM40 with Late-onset Alzheimer's disease" [Biochim. Biophys. Acta 1863/11 (2017) 2973-2986].

Zietlow K, Charalambous L, Ng I, Gagrani S, Mihovilovic M, Luo S, Rock DL, Saunders A, Roses AD, Kirby Gottschalk W.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1216. doi: 10.1016/j.bbadis.2018.01.017. Epub 2018 Jan 31. No abstract available.

PMID:
29395737
2.

Characterization of APOE and TOMM40 allele frequencies in the Japanese population.

Nishimura A, Nonomura H, Tanaka S, Yoshida M, Maruyama Y, Aritomi Y, Saunders AM, Burns DK, Lutz MW, Runyan G, Lai E, Budur K, Roses AD.

Alzheimers Dement (N Y). 2017 Sep 6;3(4):524-530. doi: 10.1016/j.trci.2017.07.003. eCollection 2017 Nov.

3.

The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease.

Zeitlow K, Charlambous L, Ng I, Gagrani S, Mihovilovic M, Luo S, Rock DL, Saunders A, Roses AD, Gottschalk WK.

Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2973-2986. doi: 10.1016/j.bbadis.2017.07.031. Epub 2017 Jul 30. Erratum in: Biochim Biophys Acta. 2018 Jan 27;:.

4.

APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans.

Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Yang J, Gaiteri C, De Jager PL, Barnes LL, Bennett DA.

PLoS One. 2017 Jul 3;12(7):e0180356. doi: 10.1371/journal.pone.0180356. eCollection 2017.

5.

Editorial overview: Molecular & genetic basis of disease.

Bonini NM, Lee EB, Wasco W, Roses AD.

Curr Opin Genet Dev. 2017 Jun;44:iv-vi. doi: 10.1016/j.gde.2017.04.003. Epub 2017 May 2. No abstract available.

PMID:
28473186
6.

The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease.

Larsen PA, Lutz MW, Hunnicutt KE, Mihovilovic M, Saunders AM, Yoder AD, Roses AD.

Alzheimers Dement. 2017 Jul;13(7):828-838. doi: 10.1016/j.jalz.2017.01.017. Epub 2017 Feb 24.

7.

TOMM40'523 variant and cognitive decline in older persons with APOE ε3/3 genotype.

Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Gaiteri C, De Jager PL, Barnes LL, Bennett DA.

Neurology. 2017 Feb 14;88(7):661-668. doi: 10.1212/WNL.0000000000003614. Epub 2017 Jan 20.

8.

The effects of PPARγ on the regulation of the TOMM40-APOE-C1 genes cluster.

Subramanian S, Gottschalk WK, Kim SY, Roses AD, Chiba-Falek O.

Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):810-816. doi: 10.1016/j.bbadis.2017.01.004. Epub 2017 Jan 6.

9.

The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants.

Saul R, Lutz MW, Burns DK, Roses AD, Chiba-Falek O.

Hum Mutat. 2016 Sep;37(9):877-83. doi: 10.1002/humu.23023. Epub 2016 Jun 27.

10.

Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults.

Wennberg AM, Spira AP, Pettigrew C, Soldan A, Zipunnikov V, Rebok GW, Roses AD, Lutz MW, Miller MM, Thambisetty M, Albert MS.

J Neurol Sci. 2016 Jun 15;365:89-95. doi: 10.1016/j.jns.2016.04.017. Epub 2016 Apr 14.

11.

The Role of Upregulated APOE in Alzheimer's Disease Etiology.

Gottschalk WK, Mihovilovic M, Roses AD, Chiba-Falek O.

J Alzheimers Dis Parkinsonism. 2016 Mar;6(1). pii: 209. Epub 2016 Feb 9. No abstract available.

12.

A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer's Disease.

Lutz MW, Sundseth SS, Burns DK, Saunders AM, Hayden KM, Burke JR, Welsh-Bohmer KA, Roses AD.

Alzheimers Dement (N Y). 2016 Jan 1;2(1):30-44.

13.

New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics.

Lutz MW, Crenshaw D, Welsh-Bohmer KA, Burns DK, Roses AD.

Curr Neurol Neurosci Rep. 2016 May;16(5):48. doi: 10.1007/s11910-016-0643-8. Review.

PMID:
27039903
14.

Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing.

Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D.

Expert Opin Drug Metab Toxicol. 2016;12(2):135-47. doi: 10.1517/17425255.2016.1133586. Epub 2016 Feb 2. Review.

PMID:
26727306
15.
16.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S.

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29. Review.

17.

APOE/TOMM40 genetic loci, white matter hyperintensities, and cerebral microbleeds.

Lyall DM, Muñoz Maniega S, Harris SE, Bastin ME, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández Mdel C, Royle NA, Starr JM, Porteous DJ, Deary IJ, Wardlaw JM.

Int J Stroke. 2015 Dec;10(8):1297-300. doi: 10.1111/ijs.12615. Epub 2015 Aug 26.

18.

A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression.

Lutz MW, Saul R, Linnertz C, Glenn OC, Roses AD, Chiba-Falek O.

Alzheimers Dement. 2015 Oct;11(10):1133-43. doi: 10.1016/j.jalz.2015.05.011. Epub 2015 Jun 13.

19.

The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging.

Gottschalk WK, Lutz MW, He YT, Saunders AM, Burns DK, Roses AD, Chiba-Falek O.

J Parkinsons Dis Alzheimers Dis. 2014 Nov;1(1). pii: 12.

20.

Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.

Crenshaw DG, Asin K, Gottschalk WK, Liang Z, Zhang N, Roses AD.

PLoS One. 2015 Feb 11;10(2):e0117973. doi: 10.1371/journal.pone.0117973. eCollection 2015.

21.

African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles.

Roses AD, Lutz MW, Saunders AM, Goldgaber D, Saul R, Sundseth SS, Akkari PA, Roses SM, Gottschalk WK, Whitfield KE, Vostrov AA, Hauser MA, Allingham RR, Burns DK, Chiba-Falek O, Welsh-Bohmer KA.

Alzheimers Dement. 2014 Nov;10(6):592-601.e2. doi: 10.1016/j.jalz.2014.06.009. Epub 2014 Sep 26.

22.

Are APOE ɛ genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter tract integrity?

Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández Mdel C, Royle NA, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ.

Transl Psychiatry. 2014 Sep 23;4:e449. doi: 10.1038/tp.2014.89.

23.

A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial.

Hayden KM, Makeeva OA, Newby LK, Plassman BL, Markova VV, Dunham A, Romero HR, Melikyan ZA, Germain CM, Welsh-Bohmer KA, Roses AD; TOMSK-DUKE Study Group Investigators.

Alzheimers Dement. 2014 Nov;10(6):760-768.e1. doi: 10.1016/j.jalz.2014.02.008. Epub 2014 Jul 22.

24.

The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes.

Greenbaum L, Springer RR, Lutz MW, Heymann A, Lubitz I, Cooper I, Kravitz E, Sano M, Roses AD, Silverman JM, Saunders AM, Beeri MS.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1492-9. doi: 10.1016/j.euroneuro.2014.06.002. Epub 2014 Jun 13.

25.

The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Linnertz C, Lutz MW, Ervin JF, Allen J, Miller NR, Welsh-Bohmer KA, Roses AD, Chiba-Falek O.

Hum Mol Genet. 2014 Sep 15;23(18):4814-21. doi: 10.1093/hmg/ddu196. Epub 2014 Apr 28.

26.

Community engagement in diverse populations for Alzheimer disease prevention trials.

Romero HR, Welsh-Bohmer KA, Gwyther LP, Edmonds HL, Plassman BL, Germain CM, McCart M, Hayden KM, Pieper C, Roses AD.

Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):269-74. doi: 10.1097/WAD.0000000000000029.

27.

New applications of disease genetics and pharmacogenetics to drug development.

Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK.

Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3. Review.

28.

Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936.

Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández Mdel C, Royle NA, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ.

Neurobiol Aging. 2014 Jun;35(6):1513.e25-33. doi: 10.1016/j.neurobiolaging.2014.01.006. Epub 2014 Jan 8.

29.

The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes.

Linnertz C, Anderson L, Gottschalk W, Crenshaw D, Lutz MW, Allen J, Saith S, Mihovilovic M, Burke JR, Welsh-Bohmer KA, Roses AD, Chiba-Falek O.

Alzheimers Dement. 2014 Sep;10(5):541-51. doi: 10.1016/j.jalz.2013.08.280. Epub 2014 Jan 15.

30.

Alzheimer's disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936.

Lyall DM, Royle NA, Harris SE, Bastin ME, Maniega SM, Murray C, Lutz MW, Saunders AM, Roses AD, del Valdés Hernández MC, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ.

PLoS One. 2013 Nov 15;8(11):e80513. doi: 10.1371/journal.pone.0080513. eCollection 2013.

31.

Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms.

Mastaglia FL, Rojana-udomsart A, James I, Needham M, Day TJ, Kiers L, Corbett JA, Saunders AM, Lutz MW, Roses AD; Alzheimer’s Disease Neuroimaging Initiative.

Neuromuscul Disord. 2013 Dec;23(12):969-74. doi: 10.1016/j.nmd.2013.09.008. Epub 2013 Sep 19.

PMID:
24103330
32.

TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial.

Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK.

Alzheimers Dement. 2013 Mar;9(2):132-6. doi: 10.1016/j.jalz.2012.10.009. Epub 2013 Jan 18. Review.

33.

Using genetics to enable studies on the prevention of Alzheimer's disease.

Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, Welsh-Bohmer KA, Brannan SK, Burns DK, Roses AD.

Clin Pharmacol Ther. 2013 Feb;93(2):177-85. doi: 10.1038/clpt.2012.222. Epub 2012 Nov 7.

34.

A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing.

Davies G, Harris SE, Reynolds CA, Payton A, Knight HM, Liewald DC, Lopez LM, Luciano M, Gow AJ, Corley J, Henderson R, Murray C, Pattie A, Fox HC, Redmond P, Lutz MW, Chiba-Falek O, Linnertz C, Saith S, Haggarty P, McNeill G, Ke X, Ollier W, Horan M, Roses AD, Ponting CP, Porteous DJ, Tenesa A, Pickles A, Starr JM, Whalley LJ, Pedersen NL, Pendleton N, Visscher PM, Deary IJ.

Mol Psychiatry. 2014 Jan;19(1):76-87. doi: 10.1038/mp.2012.159. Epub 2012 Dec 4.

PMID:
23207651
35.

Longitudinal modeling of cognitive aging and the TOMM40 effect.

Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, Roses AD.

Alzheimers Dement. 2012 Nov;8(6):490-5. doi: 10.1016/j.jalz.2011.11.006.

36.

Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.

Chiba-Falek O, Linnertz C, Guyton J, Gardner SD, Roses AD, McCarthy JJ, Patel K.

Hum Genet. 2012 Dec;131(12):1911-20. doi: 10.1007/s00439-012-1220-0. Epub 2012 Aug 17.

PMID:
22898894
37.

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging.

Hayden KM, McEvoy JM, Linnertz C, Attix D, Kuchibhatla M, Saunders AM, Lutz MW, Welsh-Bohmer KA, Roses AD, Chiba-Falek O.

Alzheimers Dement. 2012 Sep;8(5):381-8. doi: 10.1016/j.jalz.2011.10.005. Epub 2012 Aug 3.

38.

Characterization of the poly-T variant in the TOMM40 gene in diverse populations.

Linnertz C, Saunders AM, Lutz MW, Crenshaw DM, Grossman I, Burns DK, Whitfield KE, Hauser MA, McCarthy JJ, Ulmer M, Allingham R, Welsh-Bohmer KA, Roses AD, Chiba-Falek O.

PLoS One. 2012;7(2):e30994. doi: 10.1371/journal.pone.0030994. Epub 2012 Feb 16.

39.

The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.

Johnson SC, La Rue A, Hermann BP, Xu G, Koscik RL, Jonaitis EM, Bendlin BB, Hogan KJ, Roses AD, Saunders AM, Lutz MW, Asthana S, Green RC, Sager MA.

Alzheimers Dement. 2011 Jul;7(4):456-65. doi: 10.1016/j.jalz.2010.11.012.

40.

Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE ε4-negative elderly.

Pomara N, Bruno D, Sidtis JJ, Lutz MW, Greenblatt DJ, Saunders AM, Roses AD.

J Clin Psychopharmacol. 2011 Aug;31(4):544-6. doi: 10.1097/JCP.0b013e318222810e. No abstract available.

PMID:
21720235
41.

The importance of being connected.

Lutz MW, Crenshaw DG, Saunders AM, Roses AD.

J Alzheimers Dis. 2011;24(2):247-51. doi: 10.3233/JAD-2010-101765. No abstract available.

PMID:
21206004
42.

Alzheimer's disease: diagnostics, prognostics and the road to prevention.

Grossman I, Lutz MW, Crenshaw DG, Saunders AM, Burns DK, Roses AD.

EPMA J. 2010 Jun;1(2):293-303. Epub 2010 Jun 29.

43.

Healthy aging and preclinical dementia: the United States-Israel Longitudinal Database project.

Khachaturian AS, Chapman J, Farrer L, Friedland RP, Ebstein R, Grossman I, Hendler T, Hermann B, Inzelberg R, Johnson S, Khachaturian ZS, Lichter-Shapira I, Makeeva O, Mayrl R, Mizrahi E, Roses AD, Sager M, Fraifeld S.

Alzheimers Dement. 2010 Nov;6(6):475-81. doi: 10.1016/j.jalz.2010.10.001.

PMID:
21044777
44.

An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease.

Roses AD.

Arch Neurol. 2010 May;67(5):536-41. doi: 10.1001/archneurol.2010.88. Review.

45.

An epidemiologic-based survey of public attitudes towards predictive genetic testing in Russia.

Makeeva OA, Markova VV, Roses AD, Puzyrev VP.

Per Med. 2010 May;7(3):291-300. doi: 10.2217/pme.10.23.

PMID:
29776224
46.

Genetic variation at a single locus and age of onset for Alzheimer's disease.

Lutz MW, Crenshaw DG, Saunders AM, Roses AD.

Alzheimers Dement. 2010 Mar;6(2):125-31. doi: 10.1016/j.jalz.2010.01.011.

47.

Genome-wide scan of copy number variation in late-onset Alzheimer's disease.

Heinzen EL, Need AC, Hayden KM, Chiba-Falek O, Roses AD, Strittmatter WJ, Burke JR, Hulette CM, Welsh-Bohmer KA, Goldstein DB.

J Alzheimers Dis. 2010;19(1):69-77. doi: 10.3233/JAD-2010-1212.

48.

A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM.

Pharmacogenomics J. 2010 Oct;10(5):375-84. doi: 10.1038/tpj.2009.69. Epub 2009 Dec 22.

49.

Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development.

Akkari PA, Swanson TW, Crenshaw DG, Grossman I, Sundseth S, Burns DK, Roses AD.

Curr Pharm Des. 2009;15(32):3754-63. Review.

PMID:
19925426
50.

Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry.

Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, Tozzi F, Li JZ, Burmeister M, Absher D, Thompson RC, Francks C, Meng F, Antoniades A, Southwick AM, Schatzberg AF, Bunney WE, Barchas JD, Jones EG, Day R, Matthews K, McGuffin P, Strauss JS, Kennedy JL, Middleton L, Roses AD, Watson SJ, Vincent JB, Myers RM, Farmer AE, Akil H, Burns DK, Boehnke M.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7501-6. doi: 10.1073/pnas.0813386106. Epub 2009 Apr 28.

Supplemental Content

Loading ...
Support Center